Investigating the long-term effects of Belimumab in adults with lung disease related to systemic sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label extension study evaluates the long-term safety and efficacy of Belimumab in adults who have systemic sclerosis associated interstitial lung disease (SSc-ILD). Participants must have completed a prior study and will receive Belimumab to assess its tolerability, impact on lung function decline, and overall disease progression. The study aims to improve the quality of life for patients suffering from this condition through ongoing treatment. It involves self-administration of the medication or administration by a caregiver.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with SSc-ILD or other CTD-ILDs that have completed either study 218224 or 221672 through to and including the Week 52 visit and are not considered treatment failure, defined as meeting either of the following criteria:

  * Discontinuation of study medication during study 218224 or 221672 for any reason.
* Participants with SSc should have an area of uninvolved or mildly thickened skin that, in the opinion of the investigator, would allow subcutaneous (SC) injection at the abdomen or the front, middle region of the thigh.
* Participant is capable and willing to self-administer the study medication or has a caregiver/healthcare professional who is capable and willing to administer the study medication throughout the study.
* Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

Is a woman of non-childbearing potential (WONCBP) or is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\<)1 percentage (%), during the study treatment period and for at least 4 months after the last dose of study intervention. The investigator should evaluate potential for contraceptive method failure (e.g., non-compliance, recently initiated) in relationship to the first dose of study intervention.

1. A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) within 24 hours before the first dose of study intervention.
2. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
3. Additional requirements for pregnancy testing during and after study intervention are located.
4. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

   * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.

Exclusion Criteria:

* Participants of study 218224 or study 221672 who have discontinued study treatment, prior to Week 52.
* Participants who have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SSc or other CTD (i.e, cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases), or experienced an AE in study 218224 or study 221672 that could, in the opinion of the principal investigator, put the participant at undue risk.
* Participants who have developed any other medical diseases (eg, cardiopulmonary), laboratory abnormalities, or conditions (eg, poor venous access) that, in the opinion of the investigator could significantly alter the absorption, metabolism, or elimination of drugs; constitutes a risk when taking the study intervention; interferes with the interpretation of data; or it is not safe for the participant to continue on the study.
* Participants who have been exposed to ionizing radiation in excess of 10 millisievert (mSv) above background over the previous 3 year period as a result of occupational exposure or previous participation in research studies.
* QT Interval Corrected (QTc) greater than (\>) 480 millisecond (msec) at Week 52 of parent study 218224 or study 221672.

Where it's running

• GSK Investigational Site
  Los Angeles, California, United States Recruiting
• GSK Investigational Site
  New York, New York, United States Recruiting
• GSK Investigational Site
  Philadelphia, Pennsylvania, United States Recruiting
• GSK Investigational Site
  Philadelphia, Pennsylvania, United States Recruiting
• GSK Investigational Site
  Buenos Aires, Argentina Recruiting
• GSK Investigational Site
  Buenos Aires, Argentina Recruiting

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center
• Email: GSKClinicalSupportHD@gsk.com
• Phone: 877-379-3718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab for lupus nephritis

  This trial tests whether adding LUPKYNIS to other biologics (belimumab, obinutuzumab, or anifrolumab) plus a mycophenolic acid analog and a steroid can rapidly improve kidney health in adults with biopsy-proven lupus nephritis.

  Recruiting at 27 sites Phase 4 Aurinia Pharmaceuticals Inc. · La Mesa, California and 26 other locations · NCT07611214

• Early detection of progressive lung fibrosis in connective tissue diseases

  This project will test whether blood extracellular vesicle biomarkers combined with AI-analyzed HRCT scans can detect and predict progressive interstitial lung disease in adults with connective tissue diseases.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07541638

• Belimumab to mobilize memory B cells to help delistings for highly sensitized kidney transplant candidates

  A short belimumab course is being tested to see if it can reveal memory B cells that target donor HLAs, helping to decide which donors to exclude and potentially speed up getting a transplant for highly sensitized patients.

  Recruiting Phase 2 Leiden University Medical Center · Leiden · NCT07539857

• Comparing two biologic induction regimens and standard mycophenolate therapy for active proliferative lupus nephritis over six months

  This trial will test whether biologic induction therapy with belimumab or telitacicept leads to better kidney responses over six months than standard mycophenolate-based treatment in people aged 14–65 with active proliferative lupus nephritis.

  Recruiting Phase 2 Nanjing University School of Medicine · Nanjing, Jiangsu · NCT07340463

• Using capillaroscopy to help diagnose diffuse interstitial pneumonias

  We will test whether adding nailfold capillaroscopy to standard care helps doctors diagnose connective-tissue–related interstitial lung disease faster in adults newly diagnosed with pulmonary interstitial disease.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07283081

• Combining belimumab and voclosporin for proliferative lupus kidney disease

  This trial will test whether giving belimumab and voclosporin together with background mycophenolate helps people with proliferative lupus nephritis reach complete kidney remission and lets doctors stop mycophenolate sooner.

  Recruiting at 7 sites Phase 4 NephroNet, Inc. · Glendale, Arizona and 6 other locations · NCT07225387

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.